Sequent Scientific Limited — PPTs, 18-11-2025: Investor Presentation

**Business Performance & Key Financials:** SeQuent Scientific and Viyash Lifesciences merger received NCLT approval, positioning them as a major global animal health player. The combined entity showed robust Q2 FY26 performance with sales of ₹852.1 Cr (+16% YoY) and EBITDA surging to ₹189 Cr (+76% YoY), achieving a 22.2% margin. H1 FY26 saw sales at ₹1,646.2 Cr (+12.6% YoY) and EBITDA at ₹318 Cr (+48% YoY), with a healthy Net Debt to LTM EBITDA of 0.7x. Growth was broad-based across formulations, APIs, and key international markets.

**Growth Drivers & Strategy:** The merger aims to capture growth in the Companion Animal Health segment and the genericization trend in animal health, leveraging combined strengths in R&D, APIs, and formulations for CDMO business. Strategic focus includes new product launches, operational efficiencies, and expanding existing businesses.

**Recent Developments:** Beyond NCLT merger sanction, a new production block was commissioned, and a large-volume API validated. SeQuent launched Tulaject in Brazil and a new product for the US market. Viyash successfully completed multiple regulatory and customer audits, launching APIs and formulations in the US, alongside new filings.

**Management Commentary & Outlook:** Management is confident about continued healthy growth driven by new products and cost programs, already seeing synergies in manufacturing and R&D. They view the merged entity as uniquely positioned to build a world-class business, accelerate existing growth, and establish new revenue streams, with a strong focus on synergy realization over the next year.